Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr raises $90M to rewrite treatment of rare muscle disease
(3h)
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
(4h)
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
(5h)
Abbott teams with Google Health on AI-powered health insights app
(10h)
Regeneron backs $75M series A for antibody upstart Infinimmune
(21h)
BioPharma Dive
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
(1h)
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
(4h)
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
(5h)
Trump signs order seeking to upend childhood vaccine schedule
(6h)
Vaderis hauls in $152M to test an AKT-targeting drug
(6h)
Endpoints News
Two health insurers give an AI reality check
(2h)
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
(3h)
Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says
(4h)
Epicrispr secures $90M after early data on epigenetic FSHD treatment
(4h)
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
(5h)
BioSpace
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
(3h)
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
(4h)
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
(5h)
Epicrispr, Infinimmune snag combined $165M in VC cash
(5h)
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
(6h)
STAT News
Trump is counting on the health care industry to remake vaccines. They’re pushing back instead
(57m)
Trump says his executive order should restore trust in vaccines. It does the exact opposite
(1h)
How we know that splitting up the MMR vaccine could be dangerous
(3h)
Trump’s vaccine pivot overshadows food rule
(3h)
We’re reading about an FDA rejection, 340B court battles, and more
(4h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(3mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(4mo)
Drug Channels
The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America
(7h)
Informa Connect’s Medicaid Drug Rebate Program Summit
(1d)
A System of Record, or a System of Learning?
(4d)
Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts
(1w)
The Industry Doesn't Have an Access Collaboration Problem. It Has an Accountability Problem.
(2w)
European Biotechnology Magazine
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3
(1d)
Clinical Development Expert has started
(4d)
Actimed retrieves ALS drug after Faraday collapse
(5d)
Mironid lands $46M Series B to take kidney drug into clinic
(5d)
Evexta pairs ex-Merck drug with Roche’s giredestrant
(1w)
Drug Hunter
Rethinking ERα Degradation as the Driver for SERD Efficacy
(2h)
oveporexton (TAK-861)
(4d)
Regioselective Synthesis of N-Aryl Pyrazoles Stemming from an Academic-Industrial Collaboration
(5d)
BI-3406
(6d)
aleniglipron/GSBR-1290
(1w)
Labiotech.EU
Seven biotechs driving progress in Duchenne muscular dystrophy
(4h)
We asked 19 biotech leaders what breaks their deals. It wasn’t the science.
(1d)
Top biotech deals in July 2026
(4d)
Why Western pharma is sleeping on China’s circular RNA revolution
(4d)
The biggest biotech funding rounds in July 2026
(6d)
Bio IT World
A Brain Orchestra … Playing at a Range of Unsynchronized Tempos
(12h)
New CEO for PacBio, Updated Chemistry for Vega System
(4d)
‘Reproductive Resilience Hypothesis’ Highlights the Ovary as a Discovery Source in Longevity Research
(5d)
Trends from the Trenches: Why Semantics Matter in Life Sciences
(6d)
Vibrating Capsule Reveals Gut-Brain Biomarkers for Anorexia Relapse
(1w)
GEN News
Bispecific Antibody Purification’s Complexity Problem and How to Fix It
(1h)
Indiana Emerges as a Leading U.S. Biopharma Hub
(4h)
How South Carolina Became the Southeast’s Fastest Growing Biotech Hub
(4h)
The Future of Aging Research Is Longitudinal, Multiomic, and Single-Cell
(5h)
Greater Richmond’s Pharma Cluster Keeps Compounding
(5h)
Cure Today
Text a Survivor: Sally Kalksma on Life With Multiple Myeloma
(2h)
Weekly App Check-Ins Eased Fatigue in Metastatic Breast Cancer
(4h)
Divesiran Eliminates Need for Phlebotomy in 88% of Patients With Polycythemia Vera
(21h)
Cyclosporiasis Cases Top 6,700: What Patients with Cancer Need to Know
(22h)
When the Oncology Doctor Who Watched Over You Is Two Hours Away
(22h)
Contract Pharma
CPHI Unveils Pharma Sustainability Summit
(2h)
ILiAD Appoints Former GSK Exec as Chief Business Officer
(3h)
Altasciences Expands Bioanalytical Labs in North America
(4h)
Cambrex Breaks Ground on $30M Milan R&D Facility
(4h)
BMS to Build $2.3B Manufacturing Campus in Houston
(1d)
Pharma Times
Lexeo wins FDA RMAT status for LX2020
(8h)
EHP Awards 2027 open for entries
(8h)
NICE backs new blood cancer regimens
(1d)
Obsidian begins registration cohort for amsoki-cel
(1d)
Entera Bio data selected for ASBMR plenary session
(4d)
Medcity News
From Friction to Fix: Measuring What’s Breaking Payer-Provider Trust
(4h)
Which Health Tech Companies Are Getting Customer Experience Right?
(5h)
How CMS Is Tackling ‘Coverage Purgatory’ for Medical Devices
(18h)
Amazon Pharmacy Executive: Formularies are Anti-Choice
(18h)
Small Businesses Could Face Double-Digit Premium Hikes in 2027
(18h)
Chemical & Engineering News
Chemistry advances when disciplines connect
(5h)
Periodic Graphics: Caterpillars vs. plants: A chemical battle
(21h)
Memory Lane: Laboratory science before safety data sheets
(22h)
Editorial: Scientific self-governance works well. Let’s not risk it
(1d)
Obituary: John Worns
(1d)
The Pharma Letter
CellProthera inks MoU for ProtheraCytes distribution in Japan
(3h)
Long-acting therapies continue to gain momentum in HIV
(5h)
FDA rejects ITM’s ¹⁷⁷Lu-edotreotide filing
(6h)
Pharma as its own retailer
(6h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(7h)
Targeted Oncology
Study Finds Genomic Profiling Turnaround Time Improves, but Delays Persist
(24m)
Myeloma Physicians Consider Approaches to Subcutaneous Therapy
(1h)
Ravi Salgia, MD, PhD, Discusses the ADAPT-Funded IMMUNO-BIOMAP Trial in NSCLC
(4h)
Dr Salgia on Curing Advanced Non–Small Cell Lung Cancer
(19h)
FDA Advisory Committee to Review Galleri MCED Test's PMA Application
(1d)
MedWatch
Eli Lilly faces criticism for Danish new campaign
(4h)
Novo Nordisk launches once-weekly insulin treatment in the US
(5h)
Eli Lilly maintains plans for production facilities in Germany despite billion-dollar cuts
(8h)
Watch Media launches new media about the Nordic defence industry
(8h)
Covert Novo Nordisk-Lundbeck alliance recruits former Novo candidate and replaces CEO
(9h)
In The Pipeline
So How Is AI Drug Discovery Doing, Really?
(19h)
This Is Why We Run Trials, Unfortunately
(4d)
Put Your Money Down, They Say
(4d)
Target Practice on the Molecular Scale
(5d)
We Only Know Her as Mei
(6d)
Pharmaphorum
England close to eliminating hep C thanks to treatment drive
(7h)
Trump order upturns federal childhood vaccines policy
(7h)
UK is first European country to approve Lilly's Foundayo
(9h)
Ex-BioNTech execs launch 'AI-native' cancer company
(1d)
Tenax trounced by phase 3 heart failure readout
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
HIT Consultant
Why Digital Health Founders Should Stop Worrying if They Are “AI Enough”
(13h)
From “Maybe” to Baltic Gods: The Stories Behind Virus Names
(13h)
Kyndryl to Acquire Healthcare IT Leaders: Scaling AI Modernization Across Hospitals and Payors
(18h)
Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy
(1d)
Beyond Pack-Years: Why Lung Cancer Detection Demands a Shift to AI-Driven Case-Finding
(1d)
Insights: Pink Sheet
New EU Tool Helps Drug Developers Check If They Need A Joint Clinical Assessment
(1h)
UCB Gets Scottish Funding For Zilbrysq, But England’s NICE Not Convinced
(1h)
UK MHRA Sets Diversity Goal For ‘Western Authority Dominated’ PIC/S Pharmacovigilance Group
(3h)
Trump Orders Overhaul Of Childhood Vaccination Schedule, Calls For MMR Split
(8h)
DEA Proposes Down-Scheduling Some Insomnia Drugs, Denies Idorsia Bid To Eliminate Restrictions
(20h)
BioXconomy
DOJ adopts targeted approach to mergers
(2h)
RNA and ethical quandaries in Spider-Man: Brand New Day
(2h)
CMS, HRSA target 340B with new payment, rebate rules
(3h)
Innate Pharma lands $580m Sobi partnership for lymphoma therapy
(3h)
Epicrispr raises $90m to advance muscular dystrophy therapy
(5h)
BioCentury
FIH urgency in the U.S. Plus: federated learning, biotech IPOs — a BioCentury podcast
(16h)
Jazz expands neuro reach with rare epilepsy takeout: Deals Report
(18h)
Auchincloss bill would embed trials in routine care, speed FIH starts
(18h)
Silence, AbCellera emerge as best-in-class contenders as Sionna sinks
(19h)
WuXi AppTec wins preliminary injunction in 1260H case
(2d)
SCRIP
Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
(8h)
Stock Watch: Why Investors Sold Sanofi Despite The Headline Beat
(8h)
Tenax Sees A Path Forward For TNX-103 Despite Phase III LEVEL Miss
(20h)
Silence Makes Noise With Positive Divesiran Results In Polycythemia Vera
(20h)
Jazz Returns To Epilepsy Dealmaking With Actio Acquisition
(21h)